Literature DB >> 1006167

The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways.

R G Medicus, O Götze, H J Müller-Eberhard.   

Abstract

Activated Factor B, incorporated into the cobra venom factor (CVF)-dependent C3/C5 convertase, was inactivated by diisopropylfluorophosphate (DFP). Inactivation was time- and dose-dependent and was enhanced by the presence of substrate. Treatment of the zymogen of Factor B with DFP effected significant inactivation. Incorporation of [3H]diisopropylphosphate into the zymogen and into the activated form of Factor B was demonstrated after [3H]DFP treatment and subsequent electrophoresis of the proteins on polyacrylamide gels containing sodium dodecyl sulfate. Inactivation of activated C2 incorporated into the classical C5 convertase was observed on DFP treatment of the enzyme. DFP also reduced the activity of the C2 zymogen. The description of their serine proteinase nature further emphasizes the close structural and functional relationship of C2 and Factor B.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1006167     DOI: 10.1111/j.1365-3083.1976.tb03056.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  24 in total

1.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

2.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

Review 3.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

5.  Properdin factor B (Bf) polymorphism: subtyping of SS phenotypes.

Authors:  V David; R Fauchet; H Phengsavath; L Guenet; J Y Le Gall
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

6.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

7.  The reaction of iodine and thiol-blocking reagents with human complement components C2 and factor B. Purification and N-terminal amino acid sequence of a peptide from C2a containing a free thiol group.

Authors:  C Parkes; J Gagnon; M A Kerr
Journal:  Biochem J       Date:  1983-07-01       Impact factor: 3.857

8.  The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

9.  A general method for affinity purification of complement component C3b using factor H-sepharose.

Authors:  J D Scott; J E Fothergill
Journal:  Biochem J       Date:  1982-09-01       Impact factor: 3.857

10.  The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.